Clinical Trials Browser

Phase 3 × alectinib × Endocrine × Clear all

NCT03194893 2026-05-20

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Phase 3 Active not recruiting

EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Multiple Endocrine Neoplasia Type 2a